Immuron appoints CEO to Board

Latest News

Immuron (ASX:IMC), an Australian biopharmaceutical company focused on developing and commercialising oral immunoglobulin therapeutics for the treatment of gut mediated diseases, has announced the appointment of its CEO, Dr Gary Jacob, to the Board of Directors.

Dr Jacob was appointed CEO of Immuron on 19 November 2018. 

The company said his appointment to the Board "is as envisaged in his employment agreement."